



Cite this: *Org. Biomol. Chem.*, 2024, **22**, 9271

## Correction: Cu(II)-Mediated aerobic oxidative synthesis of sulfonated chromeno[4,3-c]pyrazol-4(2H)-ones


Quan Zhou,<sup>a</sup> Hai-Yan Yu,<sup>a</sup> Yaqing Zhou,<sup>b</sup> Jing-Ru Wei<sup>a</sup> and Lei Wang<sup>\*a,c</sup>

DOI: 10.1039/d4ob90142h

rsc.li/obc

Correction for 'Cu(II)-Mediated aerobic oxidative synthesis of sulfonated chromeno[4,3-c]pyrazol-4(2H)-ones' by Quan Zhou *et al.*, *Org. Biomol. Chem.*, 2022, **20**, 5575–5581, <https://doi.org/10.1039/D2OB00639A>.

The authors regret that the molecules **3ia**, **3ib** in the original article (Scheme 2) were incorrectly reported. Instead, they are *N*-sulfonated quinolin-2(1*H*)-one-3-carboxamides, which was disclosed by X-ray diffraction and reported by the authors in a recent publication.<sup>1</sup>



**Scheme 2** Scope of salicylaldehyde propiolates. Reaction conditions: **1** (0.30 mmol), **2** (0.33 mmol), Cu(OAc)<sub>2</sub> (1.0 equiv.), 1,2-dichloroethane (6.0 mL), 60 °C, air, 6 h; isolated yield of the product; <sup>a</sup> 4 mmol scale, O<sub>2</sub> (1 atm), 12 h; <sup>b</sup> With TFA (1 eq.) as additive.

The corrections to the article are detailed below.

1. The correct Scheme 2 is shown here incorporating the corrected structures for **3ia**, **3ib**.

2. In the Experimental section the corrected details for **3ia** and **3ib** are:

2-Oxo-*N*-tosyl-1,2-dihydroquinoline-3-carboxamide (**3ia**). White solid (51 mg, 49%); mp: 298–301 °C; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 8.85 (s, 1H), 7.94 (d, *J* = 8.2 Hz, 3H), 7.76–7.65 (m, 1H), 7.45 (d, *J* = 8.2 Hz, 3H), 7.33 (t, *J* = 7.5 Hz, 1H), 2.39 (s, 3H);

<sup>a</sup>Advanced Research Institute and Department of Chemistry, Taizhou University, Taizhou, Zhejiang 318000, P. R. China. E-mail: leiwang@chnu.edu.cn

<sup>b</sup>Department of Chemistry, Taizhou Jiaxin Metering and Testing Co. Ltd, Taizhou, Zhejiang 317000, P. R. China

<sup>c</sup>State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, P. R. China




$^{13}\text{C}$  NMR (101 MHz,  $\text{DMSO-}d_6$ )  $\delta$  167.3, 166.0, 151.5, 149.9, 145.1, 141.1, 139.4, 135.6, 134.9, 133.2, 128.7, 124.0, 123.9, 121.0, 26.3; HRMS (ESI) ( $[\text{M} + \text{H}]^+$ ) calcd for  $[\text{C}_{17}\text{H}_{15}\text{N}_2\text{O}_4\text{S}^+]$ : 343.0747 (100.0%), found: 343.0745 (100%).

*N*-((3-Bromophenyl)sulfonyl)-2-oxo-1,2-dihydroquinoline-3-carboxamide (**3ib**). White solid (45 mg, 37%); mp: 265–270 °C;  $^1\text{H}$  NMR (400 MHz,  $\text{DMSO-}d_6$ )  $\delta$  8.93 (s, 1H), 8.27–8.20 (m, 1H), 8.11–8.06 (m, 1H), 7.98 (m, 2H), 7.75 (t,  $J = 7.8$  Hz, 1H), 7.63 (t,  $J = 8.0$  Hz, 1H), 7.48 (t,  $J = 8.7$  Hz, 1H), 7.35 (t,  $J = 7.6$  Hz, 1H);  $^{13}\text{C}$  NMR (101 MHz,  $\text{DMSO}$ )  $\delta$  162.6, 161.6, 147.0, 141.1, 140.4, 137.4, 134.8, 132.0, 130.9, 130.8, 127.4, 124.0, 122.3, 119.1, 116.3; HRMS (ESI) ( $[\text{M} + \text{H}]^+$ ) calcd for  $[\text{C}_{16}\text{H}_{12}\text{BrN}_2\text{O}_4\text{S}]$ : 406.9696 (100%), 408.9675 (97.3%), found: 406.9696 (100%), 408.9663 (97.3%).

3. In the abstract: "... we developed a concise and facile synthesis of 2-sulfonylated chromeno [4,3-*c*]pyrazol-4(2*H*)-ones or 2,5-dihydro-4*H*-pyrazolo[4,3-*c*]quinolin-4-ones *via* Cu(II)-promoted oxidative ..." should read "... we developed a concise and facile synthesis of 2-sulfonylated chromeno[4,3-*c*]pyrazol-4(2*H*)-ones *via* Cu(II)-promoted oxidative ..."

4. The table of contents graphic should be corrected to:



5. The final sentence in the Introduction "Herein, a feasible protocol (**Scheme 1f**) was developed for sulfonylated pyrazole fused chromeno/quinolinone *via* corresponding propiolates and sulfonohydrazides" should read "Herein, a feasible protocol (**Scheme 1f**) was developed for sulfonylated pyrazole fused chromeno *via* corresponding propiolates and sulfonohydrazides".

6. Conclusion: "Such strategy provides a quick avenue to develop a drug library of chromeno/quinolinone fused with pyrazole rings." should read "Such a strategy provides a quick avenue to develop a drug library of chromeno fused with pyrazole rings."

7. The corrected structures for compounds **3ia** and **3ib** have been included in the updated ESI.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

## References

- 1 X. Chen, S.-J. Fang, Q. Zhou, W. Huang, Q.-L. Liu and L. Wang, *Org. Biomol. Chem.*, 2024, DOI: [10.1039/D4OB01071J](https://doi.org/10.1039/D4OB01071J).

